MorphoSys AG (MPSYF)
USD 73.27
(0.0%)
USD 73.27
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 430.78 Million EUR | -4.35% |
| 2022 | 450.35 Million EUR | 5.97% |
| 2021 | 425 Million EUR | 41.4% |
| 2020 | 300.57 Million EUR | 79.16% |
| 2019 | 167.76 Million EUR | 24.54% |
| 2018 | 134.7 Million EUR | 0.82% |
| 2017 | 133.61 Million EUR | 22.03% |
| 2016 | 109.49 Million EUR | 17.27% |
| 2015 | 93.36 Million EUR | 33.81% |
| 2014 | 69.77 Million EUR | 2.9% |
| 2013 | 67.81 Million EUR | 37.06% |
| 2012 | 49.47 Million EUR | -39.36% |
| 2011 | 81.59 Million EUR | 16.73% |
| 2010 | 69.9 Million EUR | 11.17% |
| 2009 | 62.87 Million EUR | 30.77% |
| 2008 | 48.08 Million EUR | 316.23% |
| 2007 | -22.23 Million EUR | -3.82% |
| 2006 | -21.41 Million EUR | 13.68% |
| 2005 | -24.81 Million EUR | -216.29% |
| 2004 | 21.33 Million EUR | 13.65% |
| 2003 | 18.77 Million EUR | -55.59% |
| 2002 | 42.27 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 288.09 Million EUR | 129.05% |
| 2023 Q1 | 110.83 Million EUR | -17.63% |
| 2023 Q4 | 125.78 Million EUR | 28.22% |
| 2023 Q3 | 98.1 Million EUR | 2.18% |
| 2023 FY | 430.78 Million EUR | -4.35% |
| 2023 Q2 | 96 Million EUR | -13.38% |
| 2022 Q3 | 116.9 Million EUR | 20.14% |
| 2022 Q4 | 134.55 Million EUR | 15.11% |
| 2022 Q1 | 101.5 Million EUR | -26.29% |
| 2022 FY | 450.35 Million EUR | 5.97% |
| 2022 Q2 | 97.3 Million EUR | -4.13% |
| 2021 Q2 | 99.5 Million EUR | 40.65% |
| 2021 FY | 425 Million EUR | 41.4% |
| 2021 Q3 | 116.12 Million EUR | 16.71% |
| 2021 Q1 | 70.74 Million EUR | -30.51% |
| 2021 Q4 | 137.7 Million EUR | 18.58% |
| 2020 Q1 | 44.44 Million EUR | -26.89% |
| 2020 Q4 | 101.79 Million EUR | 26.76% |
| 2020 Q3 | 80.3 Million EUR | 8.48% |
| 2020 FY | 300.57 Million EUR | 79.16% |
| 2020 Q2 | 74.02 Million EUR | 66.55% |
| 2019 Q4 | 60.79 Million EUR | 54.49% |
| 2019 Q1 | 32.28 Million EUR | -41.83% |
| 2019 Q2 | 35.33 Million EUR | 9.45% |
| 2019 FY | 167.76 Million EUR | 24.54% |
| 2019 Q3 | 39.35 Million EUR | 11.36% |
| 2018 Q1 | 21.88 Million EUR | -46.69% |
| 2018 Q4 | 55.5 Million EUR | 127.22% |
| 2018 Q2 | 32.73 Million EUR | 49.57% |
| 2018 FY | 134.7 Million EUR | 0.82% |
| 2018 Q3 | 24.42 Million EUR | -25.38% |
| 2017 Q1 | 26.88 Million EUR | -33.43% |
| 2017 FY | 133.61 Million EUR | 22.03% |
| 2017 Q4 | 41.05 Million EUR | 7.41% |
| 2017 Q3 | 38.22 Million EUR | 39.23% |
| 2017 Q2 | 27.45 Million EUR | 2.12% |
| 2016 Q2 | 21.68 Million EUR | -0.8% |
| 2016 FY | 109.49 Million EUR | 17.27% |
| 2016 Q4 | 40.38 Million EUR | 57.99% |
| 2016 Q3 | 25.56 Million EUR | 17.87% |
| 2016 Q1 | 21.86 Million EUR | -26.5% |
| 2015 Q4 | 29.74 Million EUR | 30.89% |
| 2015 FY | 93.36 Million EUR | 33.81% |
| 2015 Q3 | 22.72 Million EUR | -2.23% |
| 2015 Q2 | 23.23 Million EUR | 31.56% |
| 2015 Q1 | 17.66 Million EUR | -5.28% |
| 2014 Q1 | 14.52 Million EUR | -22.2% |
| 2014 FY | 69.77 Million EUR | 2.9% |
| 2014 Q4 | 18.64 Million EUR | -11.17% |
| 2014 Q3 | 20.99 Million EUR | 34.51% |
| 2014 Q2 | 15.6 Million EUR | 7.45% |
| 2013 Q4 | 18.67 Million EUR | 3.88% |
| 2013 Q2 | 16.59 Million EUR | 13.92% |
| 2013 FY | 67.81 Million EUR | 37.06% |
| 2013 Q1 | 14.57 Million EUR | 389.15% |
| 2013 Q3 | 17.97 Million EUR | 8.28% |
| 2012 Q1 | 15.24 Million EUR | -34.49% |
| 2012 Q2 | 16.46 Million EUR | 8.04% |
| 2012 Q3 | 14.71 Million EUR | -10.62% |
| 2012 Q4 | 2.97 Million EUR | -79.76% |
| 2012 FY | 49.47 Million EUR | -39.36% |
| 2011 Q1 | 17.89 Million EUR | -13.04% |
| 2011 FY | 81.59 Million EUR | 16.73% |
| 2011 Q2 | 21.66 Million EUR | 21.04% |
| 2011 Q4 | 23.26 Million EUR | 24.0% |
| 2011 Q3 | 18.76 Million EUR | -13.39% |
| 2010 Q4 | 20.58 Million EUR | 14.54% |
| 2010 FY | 69.9 Million EUR | 11.17% |
| 2010 Q1 | 14.17 Million EUR | -27.97% |
| 2010 Q2 | 17.17 Million EUR | 21.18% |
| 2010 Q3 | 17.97 Million EUR | 4.63% |
| 2009 Q3 | 15.25 Million EUR | 3.83% |
| 2009 Q4 | 19.67 Million EUR | 28.97% |
| 2009 FY | 62.87 Million EUR | 30.77% |
| 2009 Q2 | 14.69 Million EUR | 10.87% |
| 2009 Q1 | 13.25 Million EUR | 0.0% |
| 2008 FY | 48.08 Million EUR | 316.23% |
| 2007 FY | -22.23 Million EUR | -3.82% |
| 2006 FY | -21.41 Million EUR | 13.68% |
| 2005 FY | -24.81 Million EUR | -216.29% |
| 2004 FY | 21.33 Million EUR | 13.65% |
| 2003 FY | 18.77 Million EUR | -55.59% |
| 2002 FY | 42.27 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -396.376% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -8659.41% |
| SQZ Biotechnologies Company | 85.61 Million USD | -403.136% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -1357.653% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -1056.281% |
| Mesoblast Limited | 5.9 Million USD | -7198.884% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -28582.364% |
| Genus plc | 147.7 Million USD | -191.659% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -4806.808% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -32010.748% |
| Marizyme, Inc. | 19.23 Million USD | -2139.002% |
| ContraFect Corporation | 56.88 Million USD | -657.229% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -5065.849% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -9671.2% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -29031.331% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -14671.791% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -15338.173% |
| MultiCell Technologies, Inc. | 567.42 USD | -75918996.789% |
| Accustem Sciences Inc. | 3.74 Million USD | -11398.451% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -401.228% |
| EV Biologics, Inc. | 531.96 Thousand USD | -80879.495% |
| Q BioMed Inc. | 3.43 Million USD | -12434.966% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -1642.991% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -110479.501% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -16294.92% |
| Biomind Labs Inc. | 994.18 Thousand USD | -43230.108% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | -91.041% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -6312.313% |
| Skye Bioscience, Inc. | 13.54 Million USD | -3079.764% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -20926.948% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1723220.556% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -8443.76% |
| IMV Inc. | 37.7 Million USD | -1042.374% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -2590.654% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -23374.542% |
| GB Sciences, Inc. | 1.42 Million USD | -30225.759% |
| Alpha Cognition Inc. | 9.7 Million USD | -4338.469% |
| HST Global, Inc. | 140.9 Thousand USD | -305619.474% |
| CSL Limited | 3.44 Billion USD | 87.51% |
| Halberd Corporation | 74.84 Thousand USD | -575486.087% |
| Enzolytics Inc. | 2.17 Million USD | -19665.027% |
| Resverlogix Corp. | 12.71 Million USD | -3288.768% |
| Affymax, Inc. | 39.38 Million USD | -993.739% |
| SYBLEU INC | 160.87 Thousand USD | -267671.538% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -11699.91% |
| argenx SE | 1.53 Billion USD | 71.909% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -649.965% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -41162.465% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -27175.7% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -12551.477% |
| AVAX Technologies, Inc. | 7.31 Million USD | -5792.812% |
| Zenith Capital Corp. | 8.94 Million USD | -4716.953% |
| Genscript Biotech Corporation | 825.34 Million USD | 47.806% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -2472663.555% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -17444.787% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -251070.574% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -333.685% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -24380.623% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -21744.458% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -23005.936% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -3864.113% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -22325.883% |
| BioStem Technologies, Inc. | 22.97 Million USD | -1775.011% |
| ONE Bio Corp. | 6.44 Million USD | -6585.092% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -237264.046% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -32157.761% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -38194.631% |
| Agentix Corp. | 1.37 Million USD | -31303.554% |
| LadRx Corporation | 3.81 Million USD | -11201.253% |
| Cell Source, Inc. | 4.32 Million USD | -9859.438% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -103582.771% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -46545.964% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -46545.964% |
| NovAccess Global Inc. | 2.46 Million USD | -17363.392% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -17812.348% |
| Itoco Inc. | 919.14 Thousand USD | -46767.586% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -10063.711% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -38396.885% |
| Kadimastem Ltd | 2.41 Million USD | -17773.864% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -164492.031% |
| CytoDyn Inc. | 18.05 Million USD | -2285.536% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -1711450.475% |
| Mobile Lads Corp. | 554.54 Thousand USD | -77581.588% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -195639.755% |
| Qrons Inc. | 643.67 Thousand USD | -66824.892% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -30241.074% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -19218.543% |
| Rebus Holdings, Inc. | 664 Thousand USD | -64776.527% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -23617.194% |
| International Stem Cell Corporation | 5.27 Million USD | -8072.645% |
| Bioxytran, Inc. | 3.82 Million USD | -11176.533% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -818220.237% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -2117484.127% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -1087.835% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -26524.236% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -58443.035% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -13746.999% |
| Neutra Corp. | 243.82 Thousand USD | -176578.85% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -2367.664% |
| PureTech Health plc | 144.59 Million USD | -197.918% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -2002.404% |
| IXICO plc | 4.7 Million USD | -9051.904% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -4796.898% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -265.849% |
| CSL Limited | 3.89 Billion USD | 88.934% |
| Cellectis S.A. | 97.32 Million USD | -342.643% |